We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Sentinel Diagnostics

Sentinel Diagnostics develops and manufactures in-vitro diagnostic medical devices for routine analysis and specific ... read more Featured Products: More products

Download Mobile App





Sentinel Diagnostics Develops Ready-To-Use Real-Time PCR Mix for Detection of Novel Coronavirus

By LabMedica International staff writers
Posted on 18 Mar 2020
Sentinel Diagnostics (Milan, Italy) has announced that it has developed a ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease (COVID-19). More...
Sentinel has developed two kits in collaboration with the most important hospital lab for the detection and treatment of coronavirus in Italy.

Sentinel is focused on the development and production of in vitro diagnostics (IVD) for the most advanced clinical chemistry, immunochemistry and molecular diagnostics platforms. Besides its wide product portfolio in clinical chemistry, the FOB Gold® line is Sentinel’s complete solution for colorectal cancer screening, which includes patented sampling devices and analytical systems. In the last 12 years, the company has grown in the molecular diagnostics sector and has developed the proprietary technology STAT-NAT®, able to stabilize the activity of PCR mix, allowing room temperature transport and storage, performance improvement and long shelf life. STAT-NAT® can be customized for all NAT systems, from POC to central laboratory.

Sentinel’s STAT-NAT® COVID-19 assay is a freeze-dried ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease in human respiratory tract specimens in about 90 minutes. The company has developed two versions of this kit, which follow two international protocols for the highest sensitivity and specificity. STAT-NAT® COVID-19 HK kit is based on the Hong Kong protocol, while STAT-NAT® COVID-19 B assay follows the Berlin protocol. Both these kits are validated on the most common PCR instruments and have been tested on human respiratory tract specimens found positive.

“The R&D NAT team has developed and tested the COVID-19 assay by working side by side with one of the reference hospital labs for the detection and treatment of coronavirus in Italy” said Maurizio Gramegna, Chief Technology Officer at Sentinel Diagnostics. “Both STAT-NAT® COVID-19 HK and B are compliant with the international protocols and are able to detect the relevant genetic variants of Coronavirus COVID-19. We are always in touch with KOLs, in order to keep the assays up to date and even update them in case of any virus mutation.”

Related Links:
Sentinel Diagnostics


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.